Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3GNRHRMPLPDE3APDE3BPDE4APDE4BPDE4CPDE4DPPARASLC5A2
The experimentally established mechanism targets of Choline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | SLC5A7 | Q9GZV3 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | BLM | P54132 | 2/20 | 0.35 |
| ▸ | ACHE | P22303 | 2/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | BBOX1 | O75936 | 2/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | GALR3 | O60755 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Choline SCHEMBL20721723 | 0.92 | MEN1 (0.57) | MEN1KMT2ALMNACYP3A4SLC5A7 | |
| Choline SCHEMBL992915 | 0.91 | MEN1 (0.71) | MEN1KMT2ALMNACYP3A4SLC5A7 | |
| Choline SCHEMBL21800980 | 0.88 | CYP3A4 (0.77) | MEN1KMT2ALMNACYP3A4SLC5A7 | |
| Choline SCHEMBL29118960 | 0.88 | MEN1 (0.77) | MEN1KMT2ALMNACYP3A4SLC5A7 | |
| Choline SCHEMBL338525 | 0.86 | MEN1 (0.63) | MEN1KMT2ALMNACYP3A4SLC5A7 | |
| Choline SCHEMBL8893408 | 0.86 | MEN1 (0.63) | MEN1KMT2ALMNACYP3A4SLC5A7 | |
| Choline SCHEMBL3785871 | 0.84 | — | — | |
| Choline SCHEMBL5586408 | 0.84 | — | — | |
| Choline SCHEMBL14330721 | 0.84 | — | — | |
| Choline SCHEMBL17629823 | 0.84 | MEN1 (0.92) | MEN1KMT2ALMNACYP3A4SLC5A7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113493502-B | Alpha-conotoxin peptide TxIE, pharmaceutical composition and application thereof | 广西大学 | 2023-09-12 | — | — | CN | claimed |
| CN-113493502-B | Alpha-conotoxin peptide TxIE, pharmaceutical composition and application thereof | 广西大学 | 2023-09-12 | — | — | CN | disclosed |
| US-20200375929-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH CANCER, INFLAMMATION, OR IMMUNE RESPONSE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-12-03 | — | — | US | disclosed |
| EP-3668497-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH CANCER, INFLAMMATION, OR IMMUNE RESPONSE | Washington University (US) | 2020-06-24 | — | — | EP | disclosed |
| EP-2877486-B1 | PEPTIDE-BASED COMPOUNDS AND USES THEREOF TO TREAT BETA-AMYLOID ACCUMULATION | MANUS PHARMACEUTICALS CANADA LTD (CA) | 2019-05-01 | — | — | EP | disclosed |
| WO-2019036509-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH CANCER, INFLAMMATION, OR IMMUNE RESPONSE | WASHINGTON UNIVERSITY (US) | 2019-02-21 | — | — | WO | disclosed |
| EP-3418270-A1 | NOVEL BIPHENYLSULFOXIMINES AS ALLOSTERIC MODULATORS OF THE DOPAMINE D1 RECEPTOR | Universidad Complutense De Madrid (ES) | 2018-12-26 | — | — | EP | disclosed |
| US-20170266222-A1 | MODULATION OF CHRFAM7A FOR ANTI-INFLAMMATORY THERAPIES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-09-21 | — | — | US | disclosed |
| US-9718869-B2 | Peptide-based compounds and uses thereof to treat beta-amyloid accumulation | MANUS PHARMACEUTICALS (CANADA) LTD. (CA) | 2017-08-01 | — | — | US | disclosed |
| US-20150337026-A1 | PEPTIDE-BASED COMPOUNDS AND USES THEREOF TO TREAT BETA-AMYLOID ACCUMULATION | PHARMA BIO LLC (RU) | 2015-11-26 | — | — | US | disclosed |
| CN-103374066-B | Alpha B-O-conotoxin and medicine composition and application thereof | UNIV HAINAN | 2015-02-11 | — | — | CN | disclosed |
| US-8715676-B2 | Production and uses of type I ribosome inactivating proteins | BIOO SCIENTIFIC CORPORATION (US) | 2014-05-06 | — | — | US | disclosed |
| CN-103374066-A | Alpha B-O-conotoxin and medicine composition and application thereof | UNIV HAINAN | 2013-10-30 | — | — | CN | disclosed |
| CN-102552229-A | Application of compound (E)-N-[2-(3,4-dimethoxyphenyl)ethyl]-3-phenylacrylamide in preparation for medicine resisting Alzheimer disease | UNIV SHANGHAI JIAOTONG | 2012-07-11 | — | — | CN | disclosed |
| CN-102317313-A | The preparation of 1 type ribosome inactivating protein and application | BIOO SCIENT CORP | 2012-01-11 | — | — | CN | disclosed |
| US-20110236366-A1 | PRODUCTION AND USES OF TYPE I RIBOSOME INACTIVATING PROTEINS | BIOO SCIENTIFIC CORPORATION | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200375929-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH CANCER, INFLAMMATION, OR IMMUNE RESPONSE | IKBKG, IKBKB, NFKBIA | MEN1 4026/4885KMT2A 1997/4885LMNA 3320/4885 |
| US-20150337026-A1 | PEPTIDE-BASED COMPOUNDS AND USES THEREOF TO TREAT BETA-AMYLOID ACCUMULATION | APP, IAPP, TTR | MEN1 280/4885KMT2A 4614/4885LMNA 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.